CD274 and B-cell chronic lymphocytic leukemia: Lenalidomide has the ability to reverse the T cell dysfunction observed in patients with CLL in vitro, as well as to induce downregulation of PD-1 on these defective T cells and reduce PDL-1 expression by the malignant CLL clone [60•, 61].